---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-25-000009"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T14:08:31.456061+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# SELLAS Q1 net loss $5.8M; cash $28.4M; reports positive OS in Phase 2 SLS009 AML trial

## Summary
- Net loss of $5.8M ($0.07 per share) for Q1 2025 vs $9.6M ($0.21) in Q1 2024.
- Cash and cash equivalents $28.4M as of March 31, 2025; plus $4.0M from warrant exercises in April 2025.
- Phase 2 SLS009 in r/r AML: mOS 8.9 mo (AML-MRC) and 8.8 mo (venetoclax-resistant), beating historic 2.5 mo.
- Phase 3 REGAL (GPS) interim analysis supports continuation; final analysis expected 2025.
- Closed $25M registered direct offering in Jan 2025; net proceeds for working capital.

## SEC filing metadata
- accession: 0001390478-25-000009
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047825000009/0001390478-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047825000009/sls-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-25-000009
- JSON: https://secwatch.observer/filing/0001390478-25-000009.json
- Plain text: https://secwatch.observer/filing/0001390478-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.